• SPX
  • $5,957.27
  • 0.68 %
  • $40.16
  • DJI
  • $43,942.70
  • 1.23 %
  • $534.22
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $19,001.21
  • 0.18 %
  • $35.07
Ensysce Biosciences, Inc. (ENSC) Stock Price, News & Analysis

Ensysce Biosciences, Inc. (ENSC) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.59

-$0.07

(-10.08%)

Day's range
$0.57
Day's range
$0.66
50-day range
$0.1412
Day's range
$0.978
  • Country: US
  • ISIN: US2936024056
52 wk range
$0.14
Day's range
$2.06
  • CEO: Dr. D. Lynn Kirkpatrick Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -18.46
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (ENSC)
  • Company Ensysce Biosciences, Inc.
  • Price $0.59
  • Changes Percentage (-10.08%)
  • Change -$0.07
  • Day Low $0.57
  • Day High $0.66
  • Year High $2.06

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/14/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.16
  • Trailing P/E Ratio -0.17
  • Forward P/E Ratio -0.17
  • P/E Growth -0.17
  • Net Income $-10,613,074

Income Statement

Quarterly

Annual

Latest News of ENSC

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Ensysce Biosciences, Inc. Frequently Asked Questions

  • What were the earnings of ENSC in the last quarter?

    In the last quarter Ensysce Biosciences, Inc. earnings were on Wednesday, August, 14th. The Ensysce Biosciences, Inc. maker reported -$0.22 EPS for the quarter, beating analysts' consensus estimates of -$0.39 by $0.17.

  • What is the Ensysce Biosciences, Inc. stock price today?

    Today's price of Ensysce Biosciences, Inc. is $0.59 — it has decreased by -10.08% in the past 24 hours. Watch Ensysce Biosciences, Inc. stock price performance more closely on the chart.

  • Does Ensysce Biosciences, Inc. release reports?

    Yes, you can track Ensysce Biosciences, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Ensysce Biosciences, Inc. stock forecast?

    Watch the Ensysce Biosciences, Inc. chart and read a more detailed Ensysce Biosciences, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Ensysce Biosciences, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Ensysce Biosciences, Inc. stock ticker.

  • How to buy Ensysce Biosciences, Inc. stocks?

    Like other stocks, ENSC shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Ensysce Biosciences, Inc.'s EBITDA?

    Ensysce Biosciences, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Ensysce Biosciences, Inc.’s financial statements.

  • What is the Ensysce Biosciences, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -4.758116493, which equates to approximately -475.81%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Ensysce Biosciences, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Ensysce Biosciences, Inc.'s financials relevant news, and technical analysis. Ensysce Biosciences, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Ensysce Biosciences, Inc. stock currently indicates a “sell” signal. For more insights, review Ensysce Biosciences, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.